-
Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immuno
-
Nektar Therapeutics Reports Third Quarter 2022 Financial Results
-
Nektar Therapeutics Reports Second Quarter 2022 Financial Results
-
Nektar Therapeutics (NKTR) Appoints Jillian B. Thomsen as CFO
-
Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer
-
Nektar Therapeutics Reports First Quarter 2022 Financial Results
-
Nektar Therapeutics (NKTR) is implementing a cost restructuring plan
-
Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook
-
Trading Radar for 07/31: Exxon (XOM) , Tesla (TSLA), LinkedIn (LNKD), Expedia (EXPE), McKesson (MCK) Report
-
Trading Radar for 11/02: MasterCard (MA), Level 3 (LVLT), Clearwire (CLWR), MEMC Electronic Materials (WFR), Avis Budget (CAR) Report
-
Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report

